The inhibitory effect of plasma fibronectin on collagen-induced platelet aggregation.
Plasma fibronectin (Fn) has been proposed to have an antithrombotic effect, protecting against platelet and fibrinogen consumption after injury. The current study was designed to determine the effect of plasma fibronectin on collagen-induced platelet aggregation. In vitro aggregometry using an isolated homologous rat system, demonstrated a significant (P less than .05) inhibitory effect of 120 micrograms/mL Fn on platelet aggregation as induced by 60 micrograms/mL fibrillar collagen (type I). The inhibition was evidenced by a threefold increase in lag time and a significant decrease in the rate and extent of aggregation. The hypothesis was also tested using an in vivo model of collagen-induced platelet aggregation. The model used was intravenous injection of 2 mg/kg of homologous type I collagen into anesthetized Sprague-Dawley rats. Injection of collagen preincubated with 4 mg/kg Fn resulted in significantly less thrombocytopenia and fibrinogen consumption as compared with injection of collagen alone. The results of both the in vitro and in vivo studies are consistent with the proposed antithrombotic effect of plasma fibronectin.
D000818:Animals; D001792:Blood Platelets / Q000187:drug effects*; D003094:Collagen / Q000494:pharmacology*; D004164:Diphosphonates / Q000494:pharmacology; D005353:Fibronectins / Q000097:blood / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D000077268:Pamidronate; D010974:Platelet Aggregation / Q000187:drug effects*; D051381:Rats; D012995:Solubility; D013917:Thrombin / Q000494:pharmacology
D004164:Diphosphonates; D005353:Fibronectins; D003094:Collagen; D013917:Thrombin; D000077268:Pamidronate